"Shorting of healthcare stocks, including speculative biotech stocks, should be completely banned. Forget about the profit motive for a second, but these companies aim to develop products that improve the quality of life of people with acute or chronic illnesses. "
Novel concept.
But if the objective here is to maximise the opportunity to develop life-saving medical products and therapies, then what about capping the remuneration packages of the executive involved in these businesses... to, say, a still-generous $500k pa for CEOs (as opposed to $2m pa) and an industry-norm $120kpa for non-executive chairs of boards of directors (as opposed to $350kpa), to bring their compensation to levels in line with other listed companies of similar size and complexity?
All in the interests of maximising the resources of these "protected species" companies towards the business of finding cures.
And on that note, what about the issuance of in-the-money or at-the-money options to company executives? Should that also be banned? Or should managers of these sorts of businesses be perpetually in the position of all-upside, no-downside?
- Forums
- ASX - By Stock
- Mesoblast has turned a corner
"Shorting of healthcare stocks, including speculative biotech...
- There are more pages in this discussion • 601 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
55.5¢ |
Change
0.060(12.1%) |
Mkt cap ! $633.0M |
Open | High | Low | Value | Volume |
50.0¢ | 59.0¢ | 48.5¢ | $16.88M | 30.80M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 99223 | 55.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
56.0¢ | 44000 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 99223 | 0.555 |
12 | 129157 | 0.550 |
5 | 107360 | 0.545 |
16 | 329826 | 0.540 |
2 | 67148 | 0.535 |
Price($) | Vol. | No. |
---|---|---|
0.560 | 44000 | 4 |
0.565 | 310 | 1 |
0.570 | 164673 | 5 |
0.575 | 43000 | 3 |
0.580 | 226348 | 7 |
Last trade - 16.10pm 28/03/2024 (20 minute delay) ? |
|
|||||
Last
55.5¢ |
  |
Change
0.060 ( 15.7 %) |
|||
Open | High | Low | Volume | ||
50.5¢ | 59.0¢ | 48.5¢ | 11524458 | ||
Last updated 16.02pm 28/03/2024 ? |
Featured News
MSB (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online